“Biomaterials Market Report is set to have rapid growth due growing industrialization in both developed and developing nations, strong government support, suitable strategic framework, and continuous R&D at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Biomaterials Market Forecast 2019-2029: By Product (Natural, Metallic, Ceramics, Polymers), By Application (Cardiovascular, Orthopedics, Plastic Surgery), Regional and Segment Forecasts
The global Biomaterials market is poised for rapid growth between 2019 and 2029. Factors such as increased funds and subsidies from government agencies around the world for the development of new biomaterials, the growing demand for medical implants and the growing incidence of cardiovascular disease are driving the growth of the biomaterials market.
Technological innovations in the field of biomaterials are leading to the development of advanced products, which in turn is working in favor of the market. The expansion of the geriatric population base worldwide and the consequent increase in the prevalence of cardiovascular and orthopedic disorders are providing a problem to the market.
Biomaterials are now widely used in health care sectors such as cardiovascular, orthopedic, dental, plastic, wound repair, ophthalmology and neurological conditions. Furthermore, they are used in various advanced health technologies such as cosmetic surgery, tissue engineering, medical implants and advanced drug delivery.
Leading companies featured in the report include DSM; BASF SE; Evonik Industries AG.; Berkeley Advanced Biomaterials, Inc.; CAM Bioceramics BV; Carpenter Technology Corporation; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; Covalon Technologies Ltd.; Collagen Matrix, Inc.; Medtronic, Inc.; Purac Biomaterials; Ticona GmbH; Osteotech, Inc.; and Bayer AG.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.